Amylyx
Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its Co-CEO and Co-Founder. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.
Amylyx
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.